<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2454">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04435808</url>
  </required_header>
  <id_info>
    <org_study_id>20-206</org_study_id>
    <nct_id>NCT04435808</nct_id>
  </id_info>
  <brief_title>Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19</brief_title>
  <official_title>Off Label Study to Evaluate the Efficacy of Hydroxychloroquine as Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Health Care Workers at High Risk of Occupational Exposure to SARS-CoV-2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of New Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of New Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The HCW Prophylaxis (HCWP) Study, single, open and off label intervention study. Up to 350&#xD;
      participants will be assigned to group that takes HCQ or group that opts to not take study&#xD;
      medication. Participants will be UNM HEALTH SYSTEM HCW at high risk for occupational exposure&#xD;
      to SARSCoV- 2. Study timepoints will include Day 1 screening/enrollment, 30 day, 60 day, and&#xD;
      90 day assessments. Questionnaires will be collected in all timepoints.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open and off label use, interventional, single site study. The HCWP Study&#xD;
      eligibility are HCWs at high risk for SARS-CoV-2 exposure (eg MD/DO, NP, RN, and respiratory&#xD;
      therapists in ED, Pediatric ED, Urgent Care, Pediatric Urgent Care and on Covid-19 units) at&#xD;
      UNM HEALTH SYSTEM meeting all inclusion criteria. Total number of participants: 350 (Group A&#xD;
      and B) Group A: up to 275 (HCW who choose to be provided HCQ). Will receive a 600 mg loading&#xD;
      dose followed by 200 mg daily (tablets).&#xD;
&#xD;
      Group B: up to 75 (HCW who choose not to be provided HCQ)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Stopped for futility by DSMB&#xD;
  </why_stopped>
  <start_date type="Actual">April 14, 2020</start_date>
  <completion_date type="Actual">July 15, 2020</completion_date>
  <primary_completion_date type="Actual">July 15, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SARS-CoV-2 Infection</measure>
    <time_frame>3 months</time_frame>
    <description>Number of health care workers who become infected with SARS-CoV-2 as detected by PCR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptomatic vs. Asymptomatic Infection With SARS-CoV-2</measure>
    <time_frame>3 months</time_frame>
    <description>Determine the frequency of symptomatic vs. asymptomatic SARS-CoV-2 infections in health care workers during the study via serial PCR testing and symptom surveys</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occupational Health Exposure</measure>
    <time_frame>3 months</time_frame>
    <description>Assess the role of exposure levels to Covid-19 patients amongst health care workers and its impact of infection rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of Hydroxychloroquine Use on Need for Hospitalization With SARS-CoV-2 Infection</measure>
    <time_frame>3 months</time_frame>
    <description>Will assess the severity of any SARS-CoV-2 infections amongst health care workers taking and not taking hydroxychloroquine. This will include assessments of hospital admissions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of Hydroxychloroquine Use on Need for ICU Care With SARS-CoV-2 Infection</measure>
    <time_frame>3 months</time_frame>
    <description>Will assess the severity of any SARS-CoV-2 infections amongst health care workers taking and not taking hydroxychloroquine. This will include determination of the need for ICU care.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Effect Profile of Hydroxychloroquine</measure>
    <time_frame>3 months</time_frame>
    <description>Will assess the adverse effect profile of the study drug via serial surveys</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Following SARS-CoV-2 Infection</measure>
    <time_frame>3 months</time_frame>
    <description>Will collect monthly blood samples for serological analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metagenomic Next Generation Sequencing of SARS-CoV-2 Isolates</measure>
    <time_frame>3 months</time_frame>
    <description>Will perform mNGS on any recovered SARS-CoV-2 isolates from subjects to identify the genomic lineage of the virus and to compare this with SARS-CoV-2 genomes circulating in the hospital system, the community and nationally. This may provide evidence as to the source of the infection (e.g. a hospital-based infection vs. a community infection vs. a travel-associated infection out of state).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Hydroxychloroquine Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A: up to 275 health care workers who choose to take hydroxychloroquine. Will receive a 600 mg loading dose, followed by 200 mg daily (tablets).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Intervention Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Group B: Up to 75 health care workers who choose not to take hydroxychloroquine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>Hydroxychloroquine- oral administration: Duration: up to 90 days or until meeting study termination criteria. Subjects will recieve 600 mg loading dose, followed by 200 mg daily (tablets).&#xD;
Loading dose: 600 mg once for the first day Maintenance dose: 200 mg, daily</description>
    <arm_group_label>Hydroxychloroquine Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men or women â‰¥18 years of age who are UNM HEALTH SYSTEM health care workers and are&#xD;
             asymptomatic for known presenting symptoms of SARS-CoV-2:&#xD;
&#xD;
          2. UNMHS HCWs include: MD/DO, NP, RN, and respiratory therapists working in ED, Pediatric&#xD;
             ED, Urgent Care, Pediatric Urgent Care or on Covid-19 units. Study PI's will consider&#xD;
             study enrollment of HCWs from other settings, for example certain outpatient clinics&#xD;
             or inpatient units.&#xD;
&#xD;
          3. Are not positive for SARS-CoV-2 testing&#xD;
&#xD;
          4. Willing and able to comply with survey completion, scheduled visits, treatment plan,&#xD;
             and other study procedures&#xD;
&#xD;
          5. Willing and able to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known hypersensitivity to HCQ or other 4-aminoquinoline compounds&#xD;
&#xD;
          2. Currently hospitalized&#xD;
&#xD;
          3. Symptomatic with subjective fever, cough, or sore throat&#xD;
&#xD;
          4. Current medications exclude concomitant use of HCQ, for example anti-arrhythmic&#xD;
             agents, digoxin, cyclosporin, cimetidine, or tamoxifen.&#xD;
&#xD;
          5. Concomitant use of other anti-malarial treatment or chemoprophylaxis&#xD;
&#xD;
          6. History of retinopathy of any etiology&#xD;
&#xD;
          7. Psoriasis&#xD;
&#xD;
          8. Porphyria&#xD;
&#xD;
          9. Known bone marrow disorders with significant neutropenia (polymorphonuclear leukocytes&#xD;
             &lt;1500) or thrombocytopenia (&lt;100K)&#xD;
&#xD;
         10. Known liver disease&#xD;
&#xD;
         11. Known long QT syndrome&#xD;
&#xD;
         12. Use of any investigational or non-registered drug or vaccine within 30 days preceding&#xD;
             the first dose of the study drugs or planned use during the study period. There may be&#xD;
             some exceptions to requiring a 30-day washout that will be evaluated by the&#xD;
             Co-Investigators on a case by case basis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of New Mexico Health Sciences Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>June 4, 2020</study_first_submitted>
  <study_first_submitted_qc>June 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 17, 2020</study_first_posted>
  <results_first_submitted>August 10, 2020</results_first_submitted>
  <results_first_submitted_qc>November 12, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 16, 2020</results_first_posted>
  <last_update_submitted>November 12, 2020</last_update_submitted>
  <last_update_submitted_qc>November 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of New Mexico</investigator_affiliation>
    <investigator_full_name>Walter Dehority</investigator_full_name>
    <investigator_title>Associate Professor: Pediatrics Infectious Disease</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 14, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT04435808/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 19, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT04435808/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Hydroxychloroquine Arm</title>
          <description>Group A: 0 health care workers who chose to take hydroxychloroquine&#xD;
Hydroxychloroquine: Hydroxychloroquine- oral administration: Duration: up to 90 days or until meeting study termination criteria.&#xD;
Loading dose: 600 mg once for the first day Maintenance dose: 200 mg, daily</description>
        </group>
        <group group_id="P2">
          <title>No Intervention Arm</title>
          <description>Group B: 1 health care worker who chose not to take hydroxychloroquine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0">Study stopped prior to any data collection for this lone participant</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study stopped by DSMB</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>DSMB stopped the study</population>
      <group_list>
        <group group_id="B1">
          <title>Hydroxychloroquine Arm</title>
          <description>Group A: 0 health care workers who choose to take hydroxychloroquine&#xD;
Hydroxychloroquine: Hydroxychloroquine- oral administration: Duration: up to 90 days or until meeting study termination criteria.&#xD;
Loading dose: 600 mg once for the first day Maintenance dose: 200 mg, daily</description>
        </group>
        <group group_id="B2">
          <title>No Intervention Arm</title>
          <description>Group B: 1 health care workers who chose not to take hydroxychloroquine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="1"/>
                    <count group_id="B3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="1"/>
                    <count group_id="B3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="1"/>
                    <count group_id="B3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>SARS-CoV-2 Infection</title>
        <description>Number of health care workers who become infected with SARS-CoV-2 as detected by PCR</description>
        <time_frame>3 months</time_frame>
        <population>DSMB stopped trial early prior to any data collection.</population>
        <group_list>
          <group group_id="O1">
            <title>Hydroxychloroquine Arm</title>
            <description>Group A: 0 health care workers who chose to take hydroxychloroquine&#xD;
Hydroxychloroquine: Hydroxychloroquine- oral administration: Duration: up to 90 days or until meeting study termination criteria.&#xD;
Loading dose: 600 mg once for the first day Maintenance dose: 200 mg, daily</description>
          </group>
          <group group_id="O2">
            <title>No Intervention Arm</title>
            <description>Group B: 1 health care worker who chose not to take hydroxychloroquine</description>
          </group>
        </group_list>
        <measure>
          <title>SARS-CoV-2 Infection</title>
          <description>Number of health care workers who become infected with SARS-CoV-2 as detected by PCR</description>
          <population>DSMB stopped trial early prior to any data collection.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptomatic vs. Asymptomatic Infection With SARS-CoV-2</title>
        <description>Determine the frequency of symptomatic vs. asymptomatic SARS-CoV-2 infections in health care workers during the study via serial PCR testing and symptom surveys</description>
        <time_frame>3 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occupational Health Exposure</title>
        <description>Assess the role of exposure levels to Covid-19 patients amongst health care workers and its impact of infection rates</description>
        <time_frame>3 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Impact of Hydroxychloroquine Use on Need for Hospitalization With SARS-CoV-2 Infection</title>
        <description>Will assess the severity of any SARS-CoV-2 infections amongst health care workers taking and not taking hydroxychloroquine. This will include assessments of hospital admissions.</description>
        <time_frame>3 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Impact of Hydroxychloroquine Use on Need for ICU Care With SARS-CoV-2 Infection</title>
        <description>Will assess the severity of any SARS-CoV-2 infections amongst health care workers taking and not taking hydroxychloroquine. This will include determination of the need for ICU care.</description>
        <time_frame>3 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Effect Profile of Hydroxychloroquine</title>
        <description>Will assess the adverse effect profile of the study drug via serial surveys</description>
        <time_frame>3 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Following SARS-CoV-2 Infection</title>
        <description>Will collect monthly blood samples for serological analysis</description>
        <time_frame>3 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Metagenomic Next Generation Sequencing of SARS-CoV-2 Isolates</title>
        <description>Will perform mNGS on any recovered SARS-CoV-2 isolates from subjects to identify the genomic lineage of the virus and to compare this with SARS-CoV-2 genomes circulating in the hospital system, the community and nationally. This may provide evidence as to the source of the infection (e.g. a hospital-based infection vs. a community infection vs. a travel-associated infection out of state).</description>
        <time_frame>3 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Not collected</time_frame>
      <desc>Not collected</desc>
      <group_list>
        <group group_id="E1">
          <title>Hydroxychloroquine Arm</title>
          <description>Group A: 0 health care workers who chose to take hydroxychloroquine&#xD;
Hydroxychloroquine: Hydroxychloroquine- oral administration: Duration: up to 90 days or until meeting study termination criteria.&#xD;
Loading dose: 600 mg once for the first day Maintenance dose: 200 mg, daily</description>
        </group>
        <group group_id="E2">
          <title>No Intervention Arm</title>
          <description>Group B: 0 health care worker who chose not to take hydroxychloroquine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Walter Dehority</name_or_title>
      <organization>The University of New Mexico School of Medicine</organization>
      <phone>5052725535</phone>
      <email>wdehority@salud.unm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

